ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Clinical trial NCT07342478 · RECRUITING

Trial details

NCT number: NCT07342478
Sponsor: Newave Pharmaceutical Inc
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

CLL / SLL CLL (Chronic Lymphocytic Leukemia)CLL, Refractory CLL, Relapsed SLL (Small Lymphocytic Lymphoma)SLL CLL CLL Progression

Start date: 2026-04-23
Primary completion: 2029-10-30
Enrollment: 306

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.